Related Experiment Videos
Epoetin alfa and high-dose chemotherapy
1Department of Hematology-Oncology, Allegheny University Graduate Hospital, Philadelphia, PA 19146, USA.
Seminars in Oncology
|July 22, 1998
Summary
High-dose chemotherapy with bone marrow transplantation causes anemia, often requiring transfusions. Epoetin alfa shows promise in reducing red blood cell needs, particularly after allogeneic transplants, with potential benefits before treatment.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- High-dose chemotherapy with bone marrow transplantation (HDCT) frequently leads to significant anemia.
- Causes include myelosuppression and blood loss from various sources.
- Red blood cell transfusion needs vary based on transplant type and treatment protocols.
Purpose of the Study:
- To evaluate the efficacy of epoetin alfa in managing anemia post-HDCT.
- To explore strategies for reducing red blood cell transfusion requirements in patients undergoing HDCT and BMT.
Main Methods:
- Review of controlled studies on epoetin alfa use following HDCT.
- Analysis of transfusion requirements in patients receiving allogeneic and autologous BMT.
- Investigation of combination therapies and pre-HDCT epoetin alfa administration.
Main Results:
- Epoetin alfa decreased red blood cell transfusion needs in patients undergoing allogeneic BMT.
- Results were disappointing in patients receiving autologous BMT.
- Combination therapy before HDCT did not lower post-transplant transfusion requirements.
Conclusions:
- Epoetin alfa can be effective in reducing anemia-related transfusions after allogeneic BMT.
- Pre-HDCT administration of epoetin alfa may offer a novel strategy to mitigate anemia.
- Further research is needed to optimize epoetin alfa use in autologous BMT settings.